OURA ring wearable monitoring for adults with myelodysplastic syndromes
Official title: OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study
Run by Sunnybrook Health Sciences Centre · NCT06270771 · Data updated 2026-11-12
This pilot will test whether adults with MDS can wear an OURA ring regularly and upload biometric data so clinicians can link those measurements with quality of life and transfusion status.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Sunnybrook Health Sciences Centre Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | March 20, 2025 |
| Main results expected | March 20, 2026 |
| Study ends | February 1, 2027 |
| Registry record updated | July 8, 2025 |
| Trial ID | NCT06270771 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with a WHO 2022 diagnosis of MDS of any risk group who can wear a ring, operate a compatible smartphone app, and are willing to upload data—including both transfusion-dependent and non-transfusion-dependent patients with ECOG performance status ≤3—are ideal candidates.
✕Probably not a fit
Patients with ECOG >3 or with cognitive or physical impairments that prevent using the ring or smartphone are unlikely to be able to participate or derive benefit from this wearable-based monitoring.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center, single-arm feasibility pilot will enroll two cohorts (transfusion-dependent and non-transfusion-dependent MDS), each planned for 30 participants, who will be provided an OURA ring and training. Participants will wear the ring, sync data to a smartphone app, and upload biometrics weekly while completing clinical assessments and quality-of-life questionnaires at baseline and follow-up visits. The study will collect baseline demographics, disease characteristics, laboratory values, and standardized patient-reported outcome measures to correlate with ring-derived metrics. The primary feasibility hypothesis is that participants will wear the ring at least 70% of the time over a three-month period.
Why it matters
Potential benefit: If successful, this approach could provide passive, continuous data on sleep, activity, and physiologic metrics that help detect symptom changes or declines in quality of life earlier than periodic clinic visits.
How similar studies have gone: Wearable devices have shown promise in other cancer and chronic disease populations for linking activity and sleep patterns to symptoms and outcomes, but using the OURA ring specifically in MDS is largely novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged 18 or older 4. Able to read, write and speak English or French (non-English or French speaking patients may participate if appropriate translation is used) 5. Diagnosed with Myelodysplastic Syndrome using WHO 2022 criteria (12) all risk groups 6. Ability to wear the OURA ring and operate the associated smart-phone app, and willing to adhere to the study regimen Exclusion Criteria: 1. Performance status ECOG \> 3. 2. Cognitive or physical impairment preventing the usage or utilization of the OURA ring and smart phone.
Where it's running
-
Sunnybrook Health Sciences Research Centre
Toronto, Ontario, Canada Recruiting
Study contacts
- Study coordinator: Dr. Rena Buckstein, MD
- Email: rena.buckstein@sunnybrook.ca
- Phone: 416-480-5000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS
This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.
-
Combining Luspatercept with ESA for Low-Risk Myelodysplastic Syndromes
This study is testing if combining a new drug called luspatercept with existing treatments can help people with low-risk myelodysplastic syndromes who haven't responded to current therapies.
-
Registry of older patients with cancer
This study collects health information from older cancer patients to create a registry that helps improve care and research for seniors with cancer.
-
Collection of tissue, blood, and body fluid samples from patients with hematologic cancer
This study is collecting tissue, blood, and body fluid samples from patients with blood cancers to help improve cancer research and patient care.
-
Age-stratified conditioning regimens to improve outcomes in haploidentical stem cell transplant for myelodysplastic syndrome
This study tests two conditioning regimens in adults with MDS undergoing haploidentical stem cell transplant to see how age affects outcomes over one year.
-
FXS0683 in relapsed or refractory blood cancers
This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.